[Form 4] Iovance Biotherapeutics, Inc. Insider Trading Activity
Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics (IOVA), reported equity awards dated 08/06/2025. The Form 4 discloses a grant of 300,000 stock options with a $2.58 exercise price and an expiration date listed as 08/06/2035, and 150,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. Both awards are held directly following the reported transactions. The awards vest only if the reporting person remains employed: one-third vests on the one-year anniversary of the grant and the remaining two-thirds vest in eight equal quarterly installments over the following two years. The form is signed by Corleen Roche on 08/08/2025.
Corleen M. Roche, Chief Financial Officer di Iovance Biotherapeutics (IOVA), ha segnalato attribuzioni di capitale datate 08/06/2025. Il Form 4 indica una concessione di 300,000 opzioni su azioni con prezzo di esercizio di $2.58 e data di scadenza 08/06/2035, e 150,000 unit脿 azionarie vincolate (RSU), ciascuna rappresentante un diritto condizionato a una azione ordinaria. Entrambe le assegnazioni sono detenute direttamente dopo le operazioni riportate. Le assegnazioni maturano solo se la dichiarante rimane impiegata: un terzo matura al primo anniversario della concessione e i restanti due terzi maturano in otto rate trimestrali uguali nei due anni successivi. Il modulo 猫 firmato da Corleen Roche il 08/08/2025.
Corleen M. Roche, directora financiera (Chief Financial Officer) de Iovance Biotherapeutics (IOVA), inform贸 adjudicaciones de capital fechadas 08/06/2025. El Form 4 revela una concesi贸n de 300,000 opciones sobre acciones con un precio de ejercicio de $2.58 y fecha de vencimiento 08/06/2035, y 150,000 unidades de acciones restringidas (RSU), cada una representando un derecho condicional a una acci贸n com煤n. Ambas adjudicaciones se mantienen en propiedad directa tras las transacciones reportadas. Las adjudicaciones solo se consolidan si la persona informante permanece empleada: un tercio se consolida en el primer aniversario de la concesi贸n y los restantes dos tercios se consolidan en ocho cuotas trimestrales iguales durante los dos a帽os siguientes. El formulario est谩 firmado por Corleen Roche el 08/08/2025.
Iovance Biotherapeutics (IOVA)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO) Corleen M. Roche臧� 08/06/2025鞛� 鞛愲掣 氤挫儊 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. Form 4電� 頄夓偓臧� $2.58鞚� 鞀ろ啞鞓奠厴 300,000欤�鞚� 攵�鞐檧 毵岅赴鞚� 08/06/2035, 攴鸽Μ瓿� 鞝滍暅攵�欤检嫕雼渼(RSU) 150,000欤�(臧侁皝 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ)毳� 瓿店皽頃╇媹雼�. 霊� 氤挫儊 氇憪 氤搓碃霅� 瓯半灅 鞚错泟 歆侅爲 氤挫湢霅╇媹雼�. 氤挫儊鞚� 氤搓碃鞚胳澊 瓿勳啀 瓿犾毄霅� 瓴届毎鞐愲 頇曥爼霅╇媹雼�: 1/3鞚� 攵�鞐澕搿滊秬韯� 1雲� 霅橂姅 雮犾棎 頇曥爼霅橁碃, 雮橂ǜ歆� 2/3鞚� 鞚错泟 2雲� 霃欖晥 8須岇潣 霃欖澕頃� 攵勱赴氤� 頃犽秬搿� 頇曥爼霅╇媹雼�. 鞏戩嫕鞚� 08/08/2025鞐� Corleen Roche臧� 靹滊獏頄堨姷雼堧嫟.
Corleen M. Roche, directrice financi猫re (Chief Financial Officer) d'Iovance Biotherapeutics (IOVA), a d茅clar茅 des attributions de capital dat茅es 08/06/2025. Le Form 4 indique une attribution de 300,000 options sur actions avec un prix d'exercice de $2.58 et une date d'expiration au 08/06/2035, et 150,000 unit茅s d'actions restreintes (RSU), chacune repr茅sentant un droit conditionnel 脿 une action ordinaire. Les deux attributions sont d茅tenues directement apr猫s les op茅rations d茅clar茅es. Les attributions ne deviennent acquises que si la personne d茅clar茅e reste employ茅e : un tiers devient acquis 脿 l'anniversaire d'un an de l'attribution et les deux tiers restants deviennent acquis en huit versements trimestriels 茅gaux au cours des deux ann茅es suivantes. Le formulaire est sign茅 par Corleen Roche le 08/08/2025.
Corleen M. Roche, Chief Financial Officer von Iovance Biotherapeutics (IOVA), meldete Aktienzuteilungen datiert 08/06/2025. Das Form 4 gibt eine Gew盲hrung von 300,000 Aktienoptionen mit einem Aus眉bungspreis von $2.58 und einem Verfallsdatum am 08/06/2035 sowie 150,000 Restricted Stock Units (RSUs) an, wobei jede eine bedingte Anspruchsberechtigung auf eine Stammaktie darstellt. Beide Zuteilungen werden nach den gemeldeten Transaktionen direkt gehalten. Die Zuteilungen erfolgen nur, falls die meldepflichtige Person weiter besch盲ftigt bleibt: ein Drittel wird am einj盲hrigen Jahrestag der Gew盲hrung f盲llig und die verbleibenden zwei Drittel in acht gleichen viertelj盲hrlichen Tranchen 眉ber die folgenden zwei Jahre. Das Formular ist am 08/08/2025 von Corleen Roche unterzeichnet.
- 300,000 stock options granted at a $2.58 exercise price (direct beneficial ownership)
- 150,000 RSUs granted, each representing a contingent right to one share of common stock
- Clear vesting schedule: one-third at one-year anniversary, remaining two-thirds in eight equal quarterly installments over the following two years
- Awards are contingent on continued employment (vesting occurs only if the reporting person remains employed)
- 450,000 underlying shares in total (300,000 options + 150,000 RSUs) could be issued upon exercise/settlement
Insights
TL;DR Routine CFO equity grants: 300,000 options and 150,000 RSUs鈥攍imited immediate financial disclosure beyond grant terms.
The Form 4 documents standard long-term incentive awards to CFO Corleen Roche on 08/06/2025: 300,000 stock options at a $2.58 strike with an 08/06/2035 expiration and 150,000 RSUs convertible to common shares. Both holdings are reported as direct beneficial ownership following the transaction. The disclosed vesting schedule (one-third at one year; remainder in eight quarterly installments over two years) ties realization to continued employment rather than performance metrics. From a financial perspective, the filing communicates grant size, strike, and vesting but provides no valuation, tax treatment, or acceleration provisions.
TL;DR Grants are employment-contingent with multi-year vesting; governance implications are routine and disclosure is complete for a Form 4.
The filing clearly states the nature and schedule of the awards: 300,000 stock options and 150,000 RSUs, both held directly. Each RSU equals a contingent right to one share. Vesting requires continued employment and is staggered (1/3 after one year, remaining in eight quarterly installments). The option term shown (to 08/06/2035) indicates a ten-year contractual horizon from grant date. The Form 4 provides the governance-relevant facts investors need regarding timing and ownership; no accelerated vesting or other special conditions are disclosed in the explanation section.
Corleen M. Roche, Chief Financial Officer di Iovance Biotherapeutics (IOVA), ha segnalato attribuzioni di capitale datate 08/06/2025. Il Form 4 indica una concessione di 300,000 opzioni su azioni con prezzo di esercizio di $2.58 e data di scadenza 08/06/2035, e 150,000 unit脿 azionarie vincolate (RSU), ciascuna rappresentante un diritto condizionato a una azione ordinaria. Entrambe le assegnazioni sono detenute direttamente dopo le operazioni riportate. Le assegnazioni maturano solo se la dichiarante rimane impiegata: un terzo matura al primo anniversario della concessione e i restanti due terzi maturano in otto rate trimestrali uguali nei due anni successivi. Il modulo 猫 firmato da Corleen Roche il 08/08/2025.
Corleen M. Roche, directora financiera (Chief Financial Officer) de Iovance Biotherapeutics (IOVA), inform贸 adjudicaciones de capital fechadas 08/06/2025. El Form 4 revela una concesi贸n de 300,000 opciones sobre acciones con un precio de ejercicio de $2.58 y fecha de vencimiento 08/06/2035, y 150,000 unidades de acciones restringidas (RSU), cada una representando un derecho condicional a una acci贸n com煤n. Ambas adjudicaciones se mantienen en propiedad directa tras las transacciones reportadas. Las adjudicaciones solo se consolidan si la persona informante permanece empleada: un tercio se consolida en el primer aniversario de la concesi贸n y los restantes dos tercios se consolidan en ocho cuotas trimestrales iguales durante los dos a帽os siguientes. El formulario est谩 firmado por Corleen Roche el 08/08/2025.
Iovance Biotherapeutics (IOVA)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO) Corleen M. Roche臧� 08/06/2025鞛� 鞛愲掣 氤挫儊 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. Form 4電� 頄夓偓臧� $2.58鞚� 鞀ろ啞鞓奠厴 300,000欤�鞚� 攵�鞐檧 毵岅赴鞚� 08/06/2035, 攴鸽Μ瓿� 鞝滍暅攵�欤检嫕雼渼(RSU) 150,000欤�(臧侁皝 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ)毳� 瓿店皽頃╇媹雼�. 霊� 氤挫儊 氇憪 氤搓碃霅� 瓯半灅 鞚错泟 歆侅爲 氤挫湢霅╇媹雼�. 氤挫儊鞚� 氤搓碃鞚胳澊 瓿勳啀 瓿犾毄霅� 瓴届毎鞐愲 頇曥爼霅╇媹雼�: 1/3鞚� 攵�鞐澕搿滊秬韯� 1雲� 霅橂姅 雮犾棎 頇曥爼霅橁碃, 雮橂ǜ歆� 2/3鞚� 鞚错泟 2雲� 霃欖晥 8須岇潣 霃欖澕頃� 攵勱赴氤� 頃犽秬搿� 頇曥爼霅╇媹雼�. 鞏戩嫕鞚� 08/08/2025鞐� Corleen Roche臧� 靹滊獏頄堨姷雼堧嫟.
Corleen M. Roche, directrice financi猫re (Chief Financial Officer) d'Iovance Biotherapeutics (IOVA), a d茅clar茅 des attributions de capital dat茅es 08/06/2025. Le Form 4 indique une attribution de 300,000 options sur actions avec un prix d'exercice de $2.58 et une date d'expiration au 08/06/2035, et 150,000 unit茅s d'actions restreintes (RSU), chacune repr茅sentant un droit conditionnel 脿 une action ordinaire. Les deux attributions sont d茅tenues directement apr猫s les op茅rations d茅clar茅es. Les attributions ne deviennent acquises que si la personne d茅clar茅e reste employ茅e : un tiers devient acquis 脿 l'anniversaire d'un an de l'attribution et les deux tiers restants deviennent acquis en huit versements trimestriels 茅gaux au cours des deux ann茅es suivantes. Le formulaire est sign茅 par Corleen Roche le 08/08/2025.
Corleen M. Roche, Chief Financial Officer von Iovance Biotherapeutics (IOVA), meldete Aktienzuteilungen datiert 08/06/2025. Das Form 4 gibt eine Gew盲hrung von 300,000 Aktienoptionen mit einem Aus眉bungspreis von $2.58 und einem Verfallsdatum am 08/06/2035 sowie 150,000 Restricted Stock Units (RSUs) an, wobei jede eine bedingte Anspruchsberechtigung auf eine Stammaktie darstellt. Beide Zuteilungen werden nach den gemeldeten Transaktionen direkt gehalten. Die Zuteilungen erfolgen nur, falls die meldepflichtige Person weiter besch盲ftigt bleibt: ein Drittel wird am einj盲hrigen Jahrestag der Gew盲hrung f盲llig und die verbleibenden zwei Drittel in acht gleichen viertelj盲hrlichen Tranchen 眉ber die folgenden zwei Jahre. Das Formular ist am 08/08/2025 von Corleen Roche unterzeichnet.
FAQ
What did Corleen Roche report on the IOVA Form 4?
When do the options and RSUs vest for IOVA CFO Corleen Roche?
Do the RSUs convert to shares for Iovance (IOVA)?
What is the option term and exercise price reported on the Form 4?
When was the Form 4 signed by the reporting person?
